Heterocyclic Chemistry: Engineering the Core of Modern Therapeutics
Over 85% of approved small-molecule drugs rely on heterocyclic scaffolds. Synthesizing these architectures at the required purity, scale, and speed for drug discovery demands more than standard protocols.
It demands a team that anticipates and solves synthetic challenges before they stall your program.
01 — WHAT MAKES US DIFFERENT
At Oxeltis, heterocyclic synthesis is not just a capability, it is our core expertise. Modern drug discovery demands elaborate, multi-substituted heterocyclic architectures: bicyclic scaffolds, fused rings, strained systems, and N-heterocycles with defined stereocenters. We combine deep mechanistic understanding with practical synthetic mastery across a broad range of ring systems, engaging at the strategic level, contributing to route design, proposing alternatives informed by the latest advances, and adapting swiftly to biological data.
From fragment libraries to development candidates, we build scalability into routes from the outset so the chemistry that works at discovery stage carries your program all the way through to IND-enabling quantities without costly route redesign.
Key differentiators
Representative heterocyclic scaffolds in our track record
02 — CAPABILITIES
The challenges we solve and how
Each capability below directly addresses a recurring challenge in heterocyclic scaffold synthesis for drug discovery programs.
Equipment & technology highlights
Need a specialist partner for heterocycle chemistry?
From a non-commercially heterocycle to a complex lead optimization program, tell us about your project and we'll come back to you within 48 hours.